GPR160 and prostate carcinoma: Silencing of GPR160 was found to decrease viability of VCaP and LAPC-4 (p < .01) cells and moderately the viability of PC-3 prostate cancer cells (p < .05), but not RWPE-1 (Figure 5E), thus validating the rank product analysis based CSMA results.